Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO

Watchlist Manager
Crescent Biopharma Inc (Pre-Reincorporation) Logo
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Watchlist
Price: 11.85 USD -3.03% Market Closed
Market Cap: 164.6m USD

EV/EBITDA
Enterprise Value to EBITDA

-1
Current
-46.9
Median
6.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1
=
Enterprise Value
31.4m USD
/
EBITDA
-32.5m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Average EV/EBITDA: 40.2
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 430.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.9
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
807%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A